Health / Medical Topics

    HLA-A*0201-restricted TRP2-gp100-EphA2-HER2 multipeptide Vaccine

    A cancer vaccine containing four HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A*0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. (NCI Thesaurus)




    YOU MAY ALSO LIKE

    A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT),…
    Human HLA-A wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes…
    This gene is involved in immune responses and histocompatibility processes.
    A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles.
    A process in which blood or tissue samples are tested for human leukocyte antigens (HLAs). HLAs are molecules found on the surface…
    HLA class II histocompatibility antigen, DRB1-4 beta chain protein (266 aa, ~30 kDa) is encoded by the human HLA-DRB1 gene. This protein…

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact